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Mol CancChemokines influence tumor growth directly or indirectly via both angiogenesis and tumor-leukocyte in-
teractions. Platelet factor-4 (CXCL4/PF-4), which is released from α-granules of activated platelets, is the first
described angiostatic chemokine. Recently, it was found that the variant of CXCL4/PF-4 (CXCL4L1/PF-
4var) could exert a more pronounced angiostatic and antitumoral effect than CXCL4/PF-4. However, the
molecular mechanisms of the angiostatic activities of the PF-4 forms remain partially elusive. Here, we stud-
ied the biological properties of the chemically synthesized COOH-terminal peptides of CXCL4/PF-4
(CXCL4/PF-447-70) and CXCL4L1/PF-4var (CXCL4L1/PF-4var47-70). Both PF-4 peptides lacked monocyte
and lymphocyte chemotactic activity but equally well inhibited (25 nmol/L) endothelial cell motility and
proliferation in the presence of a single stimulus (i.e., exogenous recombinant fibroblast growth factor-2).
In contrast, when assayed in more complex angiogenesis test systems characterized by the presence of multiple
mediators, including in vitro wound-healing (2.5 nmol/L versus 12.5 nmol/L), Matrigel (60 nmol/L versus
300 nmol/L), and chorioallantoic membrane assays, CXCL4L1/PF-4var47-70 was found to be significantly (5-
fold) more angiostatic than CXCL4/PF-447-70. In addition, low (7 μg total) doses of intratumoral CXCL4L1/
PF-4var47-70 inhibited B16 melanoma growth in mice more extensively than CXCL4/PF-447-70. This anti-
tumoral activity was predominantly mediated through inhibition of angiogenesis (without affecting blood
vessel stability) and induction of apoptosis, as evidenced by immunohistochemical and fluorescent staining
of B16 tumor tissue. In conclusion, CXCL4L1/PF-4var47-70 is a potent antitumoral and antiangiogenic pep-
tide. These results may represent the basis for the design of CXCL4L1/PF-4var COOH-terminal–derived
peptidomimetic anticancer drugs. Mol Cancer Res; 8(3); 322–34. ©2010 AACR.Introduction
Platelet factor-4 (CXCL4/PF-4) has been identified as
a tetrameric heparin-binding protein released from the
α-granules of activated platelets long before the term che-
mokine was introduced (1). Later, small chemotactic cy-
tokines, which are essential mediators in leukocyte
migration to inflammatory sites and to secondary lym-
phoid organs, were identified and named chemokines
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er Res; 8(3) March 2010functions, influencing angiogenesis and tumor develop-
ment (3, 4). They are classified into four groups depend-
ing on the positioning of the conserved cysteines in the
NH2-terminal part—CXC, CC, CX3C, and C chemo-
kine ligands (5)—and they generally bind to G pro-
tein–coupled seven-transmembrane receptors (GPCR)
designated CXCR or CCR (6, 7). The well-characterized
interleukin-8 (CXCL8/IL-8) is classified among the ELR+
CXC chemokines (presence of the tripeptide glutamic
acid–leucine–arginine preceding the CXC motif ), which
bind to CXCR2 and chemoattract neutrophilic granulo-
cytes and exert angiogenic activity (8, 9). In contrast,
CXCL4/PF-4 belongs to the ELR− CXC chemokine
group and is angiostatic (10). Besides its angiostatic activ-
ity, CXCL4/PF-4 is implicated in different biological pro-
cesses, such as coagulation, promotion of neutrophil cell
adhesion to endothelium, and inhibition of megakaryo-
poiesis and hematopoiesis (11-13). Although CXCL4/
PF-4 was the first discovered chemokine, the mechanisms
by which it exerts its pleiotropic biological activities are
complex and remain partially elusive. The proposed re-
ceptor for CXCL4/PF-4, named CXCR3-B (14), might
Angiostatic and Antitumoral PF-4var47-70 Peptidenot mediate all its effects. The variant of CXCL4/PF-4,
encoded by a second nonallelic gene and differing in on-
ly three amino acids, is named CXCL4L1/PF-4var (15,
16) and was isolated from thrombin-stimulated platelets
(17). In a previous study, we showed that CXCL4L1/PF-
4var is also produced by osteosarcoma cells (18).
CXCL4L1/PF-4var was found to be a more potent an-
giostatic and antitumoral chemokine than CXCL4/PF-4
in different in vitro assays and in vivo models (17, 19).
Previous reports have shown that shorter COOH-termi-
nal fragments of CXCL4/PF-4 retain their angiostatic
properties (20, 21). However, because the mode of action
of both PF-4 forms is not fully understood, we designed
COOH-terminal peptides of CXCL4/PF-4 and
CXCL4L1/PF-4var, named CXCL4/PF-447-70 and
CXCL4L1/PF-4var47-70. We found that both peptides
lack monocyte and lymphocyte chemotactic response
but retain their angiostatic activity. In addition, we
showed that s imilar to the intact PF-4 forms,
CXCL4L1/PF-4var47-70 is a more potent angiostatic
and antitumoral peptide than CXCL4/PF-447-70 in differ-
ent in vitro assays and in vivo models. Finally, we provide
evidence that the antitumoral effect of CXCL4L1/PF-
4var47-70 is predominantly mediated through inhibition
of angiogenesis and induction of apoptosis.Materials and Methods
Peptide Synthesis
The human COOH-terminal CXCL4/PF-4 peptide
(CXCL4/PF-447-70: NGRKICLDLQAPLYKKIIKKLLES)
and CXCL4L1/PF-4var peptide (CXCL4L1/PF-4var47-70:
NGRKICLDLQALLYKKIIKEHLES) were prepared by
solid-phase peptide synthesis using fluorenyl-methoxy-
carbonyl (Fmoc)–protected amino groups as previously
described (22). Purification was done by reversed-phase
high-performance liquid chromatography (RP-HPLC) us-
ing a Source 5RPC column (GE Healthcare). Proteins
were eluted from the column in an acetonitrile gradient
in 0.1% trifluoroacetic acid, and UV absorption was
monitored at 220 nm. The molecular mass and the se-
quence of the peptides were confirmed by Esquire LC
electrospray ion trap mass spectrometry (MS; Bruker)
and 491 Procise cLC protein sequence analysis (Applied
Biosystems). The extracted ion chromatogram (theoretical
values of m/z for +2 to +6 ions: 1,413.7, 942.8, 707.4,
566.1, and 471.9) shows the relative amount of
CXCL4L1/PF-4var47-70 with an average Mr of 2,826. Ly-
ophilized peptides were dissolved in sterile PBS (Lonza
BioWhittaker, Cambrex Bio Science), stabilized in
0.02% (w/v) human serum albumin (HSA; Belgian Red
Cross), supplemented with 0.01% (v/v) Tween 20 (Sigma-
Aldrich), and stored at −20°C before use. Control buffer used
in all experiments was prepared the same way as the peptides
[i.e., by lyophilization of the same HPLC solvent (25%
acetonitrile/0.1% trifluoroacetic acid) and reconstitution
in PBS].www.aacrjournals.orgSDS-PAGE
The purity and molecular mass of both COOH-termi-
nal peptides were examined by SDS-PAGE (23). Different
amounts (30 and 10 ng/lane) of both peptides were loaded
on a Tris/tricine gel. The stacking, spacer, and separating gels
contained 5% total concentration of acrylamide and
bisacrylamide monomers in w/v percent (T) and 5% amount
of bisacrylamide cross-linker relative to T in w/w percent (C),
10% T and 3.3% C, and 13% T and 5% C, respectively.
Molecular mass markers (Bio-Rad Laboratories) were lyso-
zyme and aprotinin (relative molecular weights of 14.4
and 6.5 kDa, respectively). Peptides were visualized by sil-
ver staining.
Cell Cultures
Human activated T cells were obtained from peripheral
blood mononuclear cells, purified from buffy coats of
healthy donors provided by the Blood Transfusion Center
of Leuven (Leuven, Belgium) as previously described (23).
These peripheral blood mononuclear cells were stimulated
with 2 μg/mL phytohemagglutinin (Sigma-Aldrich) for 3 d
in RPMI 1640 supplemented with 10% (v/v) FCS (PAA
Laboratories). Activated lymphocytes were cultured at 2 ×
106 cells/mL for 2 to 3 wk in the presence of 50 units/mL
IL-2 (PeproTech) before use in chemotaxis assays. The hu-
man monocytic cell line THP-1 (TIB-202, American Type
Culture Collection) was grown in suspension in RPMI
1640 supplemented with 10% (v/v) FCS.
Human dermal microvascular endothelial cel ls
(HMVEC-d; Lonza Cambrex Bio Science) were cultured
following the manufacturer's instructions in endothelial
basal medium (EBM-2) supplemented with the endothelial
growth medium EGM-2MV Bullet kit (Lonza Cambrex
Bio Science). The fetal bovine aortic endothelial cell line
(GM7373) and human umbilical vein endothelial cells
(HUVEC) were cultured in DMEM plus 10% (v/v) FCS.
B16 melanoma was orthotopically propagated in
C57BL/6 mice and cultured in Eagle's MEM with Earle's
salts (Invitrogen) buffered with NaHCO3 and supplemen-
ted with 10% (v/v) FCS and L-glutamine.
In vitro Chemotaxis
The chemotactic activities of the synthetic peptides
CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 were tested
on activated T cells and THP-1 cells. Human synthetic
CXCL11/I-TAC (22) and natural human CCL2/MCP-1,
purified in our laboratory (23), were used as positive con-
trols. Chemotaxis of activated T cells was done in HBSS
supplemented with 0.1% (w/v) HSA at 2 × 106 cells/mL
in the Boyden microchamber (Neuro Probe) with fibro-
nectin-coated, polyvinylpyrrolidone-free polycarbonate
membranes (5-μm pore size; Corning Separations Divi-
sion) for 3 h at 37°C. Activated T cells that migrated
through the membrane were stained with Hemacolor
staining solutions (Merck) and counted microscopically
in 10 oil immersion fields (×500 magnification). The che-
motactic index (CI) was calculated as the number of cells
that migrated to the test chemokine divided by the numberMol Cancer Res; 8(3) March 2010 323
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324of cells that spontaneously migrated to the chemotaxis
buffer [HBSS + 0.1% (w/v) HSA]. In addition, an alterna-
tive cell migration assay with detection based on an enzy-
matic reaction was used to study chemotaxis of THP-1
cells. The multiscreen plate (Millipore Corp.) is composed
of a 96-well filter plate (5-μm pore size) and a 96-well re-
ceiver plate. Cell migration occurs through the 96-well fil-
ter plate in response to a chemotactic gradient. The THP-1
cell suspension (100 μL in 96-well filter plate at a concen-
tration of 3.5 × 106 cells/mL) and test samples (150 μL in
96-well receiver plate) were diluted in RPMI 1640 without
phenol red and L-glutamine (Lonza Cambrex Bio Science)
supplemented with 0.1% (w/v) bovine serum albumin
(BSA; endotoxin-free; Sigma-Aldrich). After 3-h incubation
at 37°C, the upper 96-well filter plate was removed and the
cells in the lower receiver plate were quantified using the
luminescence ATP detection system (Perkin-Elmer Life
and Analytical Sciences). This highly sensitive enzymatic
ATPlite assay measures the production of light caused by
the reaction of ATP, derived from the cells after lysis, with
added luciferase and D-luciferin. The emitted light is pro-
portional to the ATP concentration and the number of
cells and was measured in a luminescence reader (FL600
microtiter plate fluorescence reader; Biotek Instruments).
The CI was calculated by dividing the luminescence value
of the test sample by the luminescence value of the chemo-
taxis buffer (control).
Endothelial Cell Migration
Inhibition of endothelial cell migration in vitro has pre-
viously been described in detail (18). Briefly, confluent
monolayers of mitomycin C–treated HMVEC were
wounded with a plastic pipette tip and repair was moni-
tored microscopically after a 24-h treatment with natural
human CXCL4/PF-4, recombinant human CXCL4L1/
PF-4var, synthetic CXCL4/PF-447-70, or CXCL4L1/PF-
4var47-70 in culture medium [i.e., EBM-2 medium supple-
mented with the EGM-2MV Bullet kit containing FCS,
ascorbic acid, hydrocortisone, fibroblast growth factor
(FGF), vascular endothelial growth factor (VEGF), insu-
lin-like growth factor I, and epidermal growth factor].
The difference of the width of the individual wounds be-
fore and after treatment was scored under a microscope
and set at zero for control cultures. A scar, which was
broader compared with the control scars (inhibition of
HMVEC migration), received an inhibition score.
Time-Lapse Cell Motility Assay
Cell motility was assessed by time-lapse videomicro-
scopy. HUVECs were seeded at 150 cells/mm2 in 24-well
plates for 2 h and then stimulated with 30 ng/mL FGF-2
in DMEM plus 0.5% FCS in the presence or absence of
increasing concentrations of CXCL4/PF-447-70 or
CXCL4L1/PF-4var47-70. Constant temperature (37°C)
and CO2 concentration (5%) were maintained throughout
the experimental period by means of a heatable stage and
climate chamber. Cells were observed under an inverted
microscope (Zeiss Axiovert 200M), and phase-contrastMol Cancer Res; 8(3) March 2010snap photographs (one frame every 15 min) were digitally
recorded for 180 min. Cell paths (15-20 cells per experi-
mental point) were generated from centroid positions, and
migration parameters were analyzed with the “Migration
and Chemotaxis” tool of ImageJ software.4
Endothelial Cell Proliferation
The cell proliferation assay was done on fetal bovine
aortic endothelial GM7373 cells as described (24). Brief-
ly, subconfluent cell cultures were incubated in DMEM
containing 0.4% FCS plus 10 ng/mL FGF-2 in the pres-
ence or absence of increasing concentrations of CXCL4/
PF-447-70 or CXCL4L1/PF-4var47-70. After 24 h, cells
were trypsinized and counted in a Bürker chamber. Data
(mean ± SD of two independent experiments in tripli-
cate) were expressed as percentage of cell proliferation in-
duced by FGF-2.
Matrigel Assay
Wells of a 48-well plate (Falcon, BD Biosciences) were
coated with Matrigel (one half diluted in HMVEC culture
medium, final concentration of 10.55 mg/mL; BD Matri-
gel basement membrane matrix, high growth factor con-
centration, phenol red–free) and allowed to solidify for
30 min at 37°C. Subsequently, 55,000 HMVECs in 400
μL of EBM-2 with EGM-2MV Bullet kit were seeded in
each well and incubated with peptide at 37°C. Each pep-
tide was tested at different concentrations in triplicate. In
at least three control wells per test plate, tube formation
was allowed in pure culture medium (i.e., in the absence
of inhibitory peptide). Tube formation was monitored ev-
ery hour with transmitted light by using an Axiovert 200
M inverted microscope, equipped with an EC Plan-Neo-
fluar 10×/0.30 dry objective and a XL-3 incubator. Pic-
tures were taken with an AxioCam MRm camera and
processed with AxioVision software release 4.6.3 (Zeiss).
For each experiment, the time point chosen for evaluation
was the minimal incubation period necessary for optimal
tube formation under our experimental conditions (11-
15 h after seeding). The total length of the tubular struc-
tures formed in each well was calculated in 25 microscopic
fields. The results are expressed as the mean percentage in-
hibition of tube formation compared with the control.
CAM Assay
Fresh fertilized chicken eggs (Gallus gallus) were incubat-
ed for 3 d at 37.6°C. On day 3, albumin (3-4 mL) was
removed to detach the egg shell from the developing cho-
rioallantoic membrane (CAM) and a window was opened
in the shell exposing the CAM. The window was covered
with cellophane tape, and the eggs were further incubated.
On day 9, the peptides were applied on sterile plastic discs
(8-mm diameter), which were allowed to dry under sterile
conditions. A solution of cortisone acetate (100 μg/disc;
Certa) was added to all discs to prevent an inflammatoryMolecular Cancer Research
Angiostatic and Antitumoral PF-4var47-70 Peptideresponse. A dried control disc loaded with dilution buffer
was placed on the CAM ∼1 cm away from the disc con-
taining the peptide. Next, the windows were covered,
and the eggs were incubated for 2 more days. On day
11, the eggs were opened, the CAM was removed, and an-
giogenesis was assessed. Pictures of each CAM were taken
under a stereomicroscope (7.5×, Moticam 2300) using a
digital camera (Motic Mc camera 2.1). All vessels intersect-
ing two concentric circles positioned in the treated area
were counted double blind and independently by two in-
vestigators. Results are represented as the mean percentage
inhibition of the number of blood vessels intersecting the
test disc compared with the control disc.
In addition, peptides were tested for their ability to in-
hibit FGF-2–induced angiogenesis in the gelatin sponge
CAM assay. Therefore, at day 9 of embryonic develop-
ment, 2 mm3 sterilized gelatin sponges (Gelfoam, Upjohn)
containing 5 μg peptide (CXCL4/PF-447-70 or CXCL4L1/
PF-4var47-70) with or without 500 ng FGF-2 (Sigma-
Aldrich) were placed on top of the CAM. After 48 h,
CAMs were fixed in ovo with 4% paraformaldehyde in
PBS for 1 h, dehydrated in graded ethanol, embedded in
paraffin, and serially sectioned at 7 μm according to a
plane parallel to their surface. Next, sections were stained
with H&E. To determine the number of blood vessels, pic-
tures of the CAM tissue around the gelatin sponge were
taken at a ×100 magnification (Zeiss Imager Z.1 micro-
scope). Results are expressed as the mean number of blood
vessels (counted double blind by two independent investi-
gators) ± SEM.
Tumor Model
Experiments were conducted with 6- to 8-wk-old female
athymic nu/nu mice (NMRI background, Elevage Janvier)
kept in a specific pathogen-free environment (three inde-
pendent experiments). B16 melanoma cells in log phase (2
× 106 resuspended in 200 μL PBS) were injected s.c. on
day 0 in the right dorsal flank. Animals were treated intra-
tumorally with control, 1 μg CXCL4/PF-447-70, or 1 μg
CXCL4L1/PF-4var47-70 three times a week starting from
day 1 (total dose equals 7 μg peptide/mouse). The external
tumor volume was measured with calipers thrice a week
and calculated using the following formula: (4πab2)/3 (a
and b are the largest and smallest radius, respectively).
On day 17, mice were sacrificed and tumors were resected.
The exact tumor volume, based on three measured radii (a,
b, and c), was calculated by the following formula: (4πabc)/
3. The resected tumor weight was also determined. Animal
experiments were approved by the local animal ethic com-
mittee (University of Leuven, Leuven, Belgium) and con-
ducted in conformity with the Belgian and European
guidelines for the protection of animals used for scientific
purposes.
Tumor Tissue Analysis for Endothelial Cells, Pericytes,
and Apoptosis
For immunohistochemical analysis of B16 tumor vascu-
lature (two independent experiments), tumors were har-www.aacrjournals.orgvested and snap frozen in liquid N2, and sections were
analyzed for the presence of blood vessels reacting with
rat anti-mouse CD31 antibody (BD Biosciences) using
the anti-rat immunoglobulin horseradish peroxidase detec-
tion kit from Pharmingen (BD Biosciences) followed by a
counterstain with Harris' hematoxylin. Transmitted light
microscopy of the whole tumor sections was done on an
Axiovert 200 M with an EC Plan-Neofluar 10×/0.30 dry
objective. Pictures were taken with an AxioCam MRc5
camera (2584 × 1936 color) and processed with Axio-
Vision software release 4.6.3. The number of small (area
<145.8 μm2), medium-size (area between 145.8 and
2,916 μm2), and large (area >2,916 μm2) blood vessels
was counted semiautomatically with the AutoMeasure Plus
module, double blind, and independently by two investi-
gators. In addition, vessel stabilization was analyzed by
staining of pericytes. Frozen sections were blocked in
PBS containing 5% normal goat serum, 0.01% Tween
20, and 0.2% BSA. Next, sections were incubated with
rat monoclonal anti-CD31 antibody (1:400) and mouse
monoclonal α-smooth muscle actin antibody (1:250;
Sigma-Aldrich) in PBS supplemented with 0.2% BSA.
After overnight incubation at 4°C, sections were washed
with PBS/0.01% Tween 20/0.1% BSA and incubated
overnight at 4°C with Alexa Fluor 350–conjugated goat
anti-rat IgG (1:450 diluted in PBS with 0.2% BSA; Mo-
lecular Probes, Invitrogen) and Alexa Fluor 647–conjugat-
ed donkey anti-mouse IgG (1:1,500; Molecular Probes).
Finally, slides were washed and mounted.
For the detection of apoptotic cells in tumor tissue, we
used the terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling (TUNEL) assay with the ApoAlert
DNA fragmentation kit (Clontech). Cell nuclei were
stained with 1.1 μmol/L 4′,6-diamidino-2-phenylindole
(DAPI; Sigma-Aldrich). Fluorescence microscopy was
done with an Axiovert 200 M equipped with a Lambda
DG-4 light source (Sutter Instrument Co.), DAPI and
fluorescein filter sets, an EC Plan-Neofluar 10×/0.30 dry
objective, and an AxioCam MRm camera (1292 × 968
mono). The whole tumor section was automatically ana-
lyzed for apoptosis. Data are expressed as a percentage of
the apoptotic surface area (green) compared with the total
surface area (blue).
Statistical Analysis
All data were analyzed using Statistica software (StatSoft,
Inc.). All results were evaluated by the Mann-Whitney U
test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
Results
Preparation of COOH-Terminal Peptides of CXCL4/
PF-4 and CXCL4L1/PF-4var
COOH-terminal peptides of human CXCL4/PF-4 and
CXCL4L1/PF-4var, abbreviated CXCL4/PF-447-70 and
CXCL4L1/PF-4var47-70, were prepared by solid-phase
peptide synthesis using Fmoc-protected amino groups
(22). Final purification was done by RP-HPLC using aMol Cancer Res; 8(3) March 2010 325
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326Source 5RPC column. CXCL4L1/PF-4var47-70 was eluted
between 24% and 26% acetonitrile. Part of the column
effluent was split to an electrospray ion trap mass spec-
trometer to determine the average molecular mass (Mr).
The averaged MS spectra of CXCL4L1/PF-4var47-70
shown in Fig. 1 indicate the charges of the detected ions
(+3 to +5) and the deconvoluted spectrum that was calcu-
lated from these charged ions. MS, in combination with
NH2-terminal amino acid sequencing, confirmed the pu-
rity and the exact sequence of both CXCL4/PF-447-70 and
CXCL4L1/PF-4var47-70. In addition, the purity and the
molecular mass of both peptides were confirmed by
SDS-PAGE.
The COOH-Terminal Peptides of Human CXCL4/PF-4
and CXCL4L1/PF-4var Are Poor Chemoattractants but
Potent Angiostatic Factors In vitro
CXC chemokines are potent chemoattractants for either
neutrophils (e.g., CXCL8/IL-8) or activated T lympho-
cytes (e.g., CXCL10/IP-10). We have previously shown
that both CXCL4/PF-4 and CXCL4L1/PF-4var are unable
to stimulate phagocyte migration in vitro (18). CXCL4/
PF-447-70 and CXCL4L1/PF-4var47-70 were now tested
for their potential to chemoattract activated T cells in
the microchamber chemotaxis assay. It was found that
CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 are not
chemotactic at all on activated T cells. In contrast, the
CXCR3 ligand CXCL11/I-TAC was still attracting T cells
at 10 nmol/L (Fig. 2A). Next, it was verified whether
CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 induce
chemotaxis of monocytic THP-1 cells in the Millipore sys-
tem. CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 were
not chemotactic for THP-1 cells, whereas the CC chemo-
kine CCL2/MCP-1 was very effective on monocytic cells,
as a CI of 7 was observed at only 0.3 nmol/L (Fig. 2B).
We also verified whether endothelial cell migration and
motility, important prerequisites for angiogenesis, were in-
hibited by CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70.
First, it was shown that, in sharp contrast to the lack of
monocyte and lymphocyte chemotactic activity, both pep-
tides inhibited endothelial cell migration following the me-
chanical wounding of a HMVEC monolayer in the
presence of multiple growth factors (Fig. 2C). Interestingly,
CXCL4L1/PF-4var47-70 exerted a significant effect at doses
as low as 2.5 nmol/L, whereas a 5-fold higher dose was re-
quired for CXCL4/PF-447-70 (Fig. 2D). As a control,
CXCL4/PF-4 and CXCL4L1/PF-4var were also tested in
this assay. The results confirm that CXCL4L1/PF-4var in-
hibits endothelial cell migration at 1 nmol/L, being there-
fore a 20-fold more potent inhibitor than CXCL4/PF-4
(18, 19). Next, it was found that both PF-4 peptides (from
5 nmol/L onwards) significantly inhibited FGF-2–induced
HUVEC motility as observed by time-lapse microscopy
(Fig. 3A). In addition, the effect of CXCL4/PF-447-70
and CXCL4L1/PF-4var47-70 on FGF-2–stimulated bovine
aortic endothelial GM7373 cell proliferation was investi-
gated. Both peptides inhibited FGF-2–induced GM7373
cell proliferation in a similar manner, ±40% inhibition be-Mol Cancer Res; 8(3) March 2010ing observed when CXCL4/PF-447-70 or CXCL4L1/PF-
4var47-70 was tested at 25 nmol/L (Fig. 3B).
We conclude that CXCL4/PF-447-70 and CXCL4L1/
PF-4var47-70 are potent angiostatic peptides rather than
inflammatory mediators responsible for monocyte or lym-
phocyte recruitment, and depending on the test system and
the experimental conditions, CXCL4L1/PF-4var47-70 was
found to be more potent than CXCL4/PF-447-70.
CXCL4L1/PF-4var47-70 Is a Broad-Spectrum
Angiogenesis Inhibitor In vitro and In vivo
To better evaluate their angiostatic activities, CXCL4/
PF-447-70 and CXCL4L1/PF-4var47-70 were further inves-
tigated in a morphogenic test on Matrigel in vitro and in
the chick embryo CAM assay in vivo. HMVECs grownFIGURE 1. Purification of synthetic CXCL4L1/PF-4var47-70 by RP-HPLC
and MS. A, peptide was recovered from the RP-HPLC column in an
acetonitrile gradient (0-80%) and UV absorbance was monitored at
220 nm (expressed as absorption units). Part of the column effluent
was split to a mass spectrometer. The extracted ion chromatogram
shows the relative amount of CXCL4L1/PF-4var47-70 with an average
Mr of 2,826. The purity and Mr of CXCL4L1/PF-4var
47-70 in a pool from
fraction 18 to 22 (30 and 10 ng/lane) is shown on SDS-PAGE (inset).
Molecular mass markers represent lysozyme (14.4 kDa) and aprotinin
(6.5 kDa). B, averaged MS spectrum (m/z versus abundance) of
CXCL4L1/PF-4var47-70–containing fractions eluting between 18 and
22 min. The charge and mass of the detected ions (+ 3 to + 5) are
indicated on top of the peaks and the deconvoluted spectrum is given as
an inset.Molecular Cancer Research
FIGURE 2. Effect of CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 on the migration of activated T cells, monocytic THP-1 cells, and endothelial cells.
Synthetic CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 were tested for their ability to induce migration of activated T cells. A, CXCL11/I-TAC was used as
positive control. B, synthetic CXCL4/PF-447-70, CXCL4L1/PF-4var47-70, and CXCL11/I-TAC were tested in the THP-1 cell chemotaxis assay in parallel
with CCL2/MCP-1 as a positive control. Results represent the mean CI (± SEM) of three or more independent experiments conducted in triplicate wells.
HMVEC monolayers were wounded and repair was monitored after treatment with natural human CXCL4/PF-4, recombinant human CXCL4L1/PF-4var,
CXCL4/PF-447-70, or CXCL4L1/PF-4var47-70. C, representative microphotographs (two per condition) of inhibition of endothelial cell migration by 300 nmol/L
of CXCL4/PF-447-70 or CXCL4L1/PF-4var47-70 are shown. Scale bar, 200 μm. D, results represent average inhibition scores (IS) ± SEM from four or
more independent experiments in duplicate. *, P < 0.05; **, P < 0.01; ***, P < 0.001, Mann-Whitney U test.
Angiostatic and Antitumoral PF-4var47-70 Peptidein vitro on Matrigel in the presence of a growth factor cock-
tail organize in capillary-like tubuli and form cords, which
develop into a three-dimensional branching network.
CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 were added
to the endothelial cell suspension, and after ∼13 hours, a
significant inhibition of tube formation was observed from
60 nmol/L of CXCL4L1/PF-4var47-70 onwards, whereas
CXCL4/PF-447-70 was only able to reduce the length of
Matrigel networks from 300 nmol/L onwards (Fig. 4A
and B). Thus, in analogy with the wound-healing assay,
CXCL4L1/PF-4var47-70 is 5-fold more potent than
CXCL4/PF-447-70 as inhibitor of endothelial cell morpho-
genesis in the Matrigel assay. Further, we tested both pep-
tides in the CAM assay, a widely used in vivo model for
angiogenesis. Discs containing different amounts of
CXCL4/PF-447-70, CXCL4L1/PF-4var47-70 (25, 5, or
1 μg), or control solution were positioned onto the CAM
at day 9 of incubation. CXCL4L1/PF-4var47-70 at 25 or 5
μg reduced the spontaneous formation of blood vesselswww.aacrjournals.org(46.0 ± 4.0% or 30.7 ± 4.8% reduction in the number of
blood vessels compared with the control; Fig. 4C and E).
In contrast, CXCL4/PF-447-70, tested at different concentra-
tions (25, 5, or 1 μg), was not able to inhibit the outgrowth
of new capillaries (data not shown). In addition, an alterna-
tive CAM assay in which specific stimuli, in casu FGF-2, are
incorporated in gelatin sponges was done to further compare
the two peptides on growth factor–induced angiogenesis
in vivo. The angiogenic effect of FGF-2 (500 ng) was inhib-
ited more effectively by 5 μg of CXCL4L1/PF-4var47-70
(75.7 ± 9.9% inhibition) compared with CXCL4/PF-447-70
(47.0 ± 11.5%; Fig. 4D), thus confirming that CXCL4L1/
PF-4var47-70 is a more potent angiostatic peptide.
Comparison of the Angiostatic CXCL4/PF-447-70 and
CXCL4L1/PF-4var47-70 COOH-Terminal Peptides for
the Inhibition of B16 Melanoma Growth in Nude Mice
Because CXCL4L1/PF-4var47-70 has stronger angiostatic
properties than CXCL4/PF-447-70, as evidenced inMol Cancer Res; 8(3) March 2010 327
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328different angiogenesis assays (see above), we wanted to ver-
ify whether CXCL4L1/PF-4var47-70 could also exert a
more pronounced antitumoral activity. Therefore, nude
mice were injected s.c. with 2 × 106 B16 melanoma cells
and then intratumorally treated (thrice per week) with
1 μg CXCL4/PF-447-70, 1 μg CXCL4L1/PF-4var47-70, or
control buffer. Reduced tumor growth (determined by ex-
ternal measurement thrice per week) was observed in the
CXCL4L1/PF-4var47-70 group compared with the control
group from day 9 onwards (Fig. 5A). On day 17, when
mice were sacrificed and tumors were resected, a significant-
ly smaller tumor volume and tumor weight was found in
the CXCL4L1/PF-4var47-70–treated mice compared with
the control mice (Fig. 5B and C). No difference in tumor
development, and final tumor volume and weight (day 17)
could be observed between the CXCL4/PF-447-70 (7 μg
total dose)–treated mice and control mice. Next, it was
verified whether the antitumoral activity of CXCL4L1/
PF-4var47-70 was mediated through inhibition of angiogen-
esis. Immunohistochemical evaluation of the intratumoral
microvasculature by anti-CD31 staining showed a signifi-
cantly lower number of small and medium-size intratumor-
al blood vessels in CXCL4L1/PF-4var47-70–treated mice
compared with the control mice (Fig. 6A and B). There
was no significant difference in the number of large blood
vessels between the two groups. Again, at the dose used, no
significant effect of CXCL4/PF-447-70 was seen on neovas-
cularization within the tumor. In addition, vessel stabiliza-
tion was evaluated by double immunofluorescent staining
with anti-CD31 and anti–α-smooth muscle actin antibo-
dies. Staining of B16 melanoma sections of control and
peptide-treated mice revealed that almost all vessels were
equally well stabilized by pericytes. Despite the change in
number of small and medium-size blood vessels, no differ-
ence in percentage α-smooth muscle actin+ CD31+ small
and medium-size vessels was observed between control,
CXCL4/PF-447-70–treated, and CXCL4L1/PF-4var47-70–
treated mice. In addition, all large blood vessels of control,
CXCL4/PF-447-70–treated, and CXCL4L1/PF-4var47-70–
treated mice were stabilized by pericytes (Fig. 6C and D).
Further, staining of the whole tumor section for the detec-
tion of apoptotic cells was done using the TUNEL assay.
Data are expressed as the percentage of the apoptotic sur-
face area (green) compared with the total surface area of the
tumor slide. The percentage of cells undergoing apoptosis
was significantly higher in the CXCL4L1/PF-4var47-70–
treated tumors (7.8 ± 2.7%), but not in the CXCL4/PF-
447-70 group (4.2 ± 1.6%), compared with the control
group (1.0 ± 0.2%; Fig. 7A and B). Taken together, these
data show a clear inhibition of angiogenesis and an induc-
tion of apoptosis by CXCL4L1/PF-4var47-70, resulting in
significantly reduced tumor growth.Discussion
Chemokines affect tumor development indirectly by in-
fluencing angiogenesis and tumor-leukocyte interactions,Mol Cancer Res; 8(3) March 2010as well as directly by influencing tumor transformation,
survival, growth, invasion, and metastasis (4, 25). The role
played by chemokines is rather complex, as some chemo-
kines may favor tumor growth and progression, whereas
others may enhance antitumor immunity. In addition, che-
mokine receptors contribute to metastasis of tumor cells in
tissue where the corresponding chemokine is expressed,
like for the CXCR4-CXCL12/SDF axis (26, 27). In this
study, we investigated the angiostatic and antitumoral
activities of the COOH-terminal peptides of human
CXCL4/PF-4 and CXCL4L1/PF-4var, designated
CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70. These
peptides were chemically synthesized and purified by RP-
HPLC, and their purity, relative mass, and the exact se-
quence were confirmed by SDS-PAGE, MS, and sequence
analysis (Fig. 1). CXCL4L1/PF-4var differs from CXCL4/
PF-4 in only three amino acids located in the COOH-
terminal region (i.e., leucine instead of proline on position
58, glutamic acid versus lysine on position 66, and histi-
dine instead of leucine on position 67).FIGURE 3. Effect of CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 on
FGF-2–induced endothelial cell motility and proliferation. A, different
concentrations of CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 were
tested for their ability to inhibit FGF-2 (30 ng/mL)–induced HUVEC
motility by time-lapse microscopy. Results are expressed as average
accumulated distance ± SD from two independent experiments in
triplicate. B, CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 were tested
for their ability to inhibit FGF-2 (10 ng/mL)–induced GM7373 cell
proliferation. Data are expressed as mean percentage cell proliferation
induced by FGF-2 ± SD from two independent experiments in triplicate.Molecular Cancer Research
FIGURE 4. Effect of CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 on endothelial cell tube formation in Matrigel and on blood vessel formation in the
CAM assay. A, different concentrations of CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 were tested in the Matrigel assay. Results are expressed as the
mean percentage inhibition of the total length of tubes formed in peptide-treated wells compared with the total length of tubes in the buffer-treated
wells ± SEM from three or more independent experiments in triplicate. *, P < 0.05; **, P < 0.01; ***, P < 0.001, Mann-Whitney U test. B, representative
microphotographs showing inhibition of tube formation by 7,500 nmol/L CXCL4/PF-447-70 and 7,500 or 1,500 nmol/L CXCL4L1/PF-4var47-70. Scale bar,
500 μm. C, discs containing CXCL4/PF-447-70 or CXCL4L1/PF-4var47-70, and control solution were applied onto the CAM. Two days later, inhibition of
vascularization was evaluated. Results are represented as the mean percentage inhibition of the number of blood vessels intersecting the test disc
compared with the control disc ± SEM (eight or more eggs per condition from two or more independent experiments). **, P < 0.01, Mann-Whitney U test.
D, gelatin sponges containing 500 ng FGF-2 in combination with 5 μg CXCL4/PF-447-70 or CXCL4L1/PF-4var47-70 were applied on the CAM. Results
are expressed as the mean percentage inhibition of the number of blood vessels in gelatin sponges containing peptide plus FGF-2 compared with the
number of blood vessels in FGF-2–containing gelatin sponges ± SEM (nine or more eggs per condition from two independent experiments). ***, P < 0.001,
Mann-Whitney U test. E, representative photographs showing spontaneous angiogenesis on the control disc and inhibition of angiogenesis by 25 or 5 μg
of CXCL4L1/PF-4var47-70 but not by 1 μg of CXCL4L1/PF-4var47-70. Some blood vessels are indicated by arrows.
Angiostatic and Antitumoral PF-4var47-70 PeptideBecause chemokines are well-known chemoattractants
for phagocytes and lymphocytes (7), both COOH-termi-
nal peptides were tested for their potential to chemoattract
activated T cells and monocytic THP-1 cells. It was found
that CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 lack
lymphocyte and monocyte chemotactic activity, whereas
CXCL11/I-TAC and CCL2/MCP-1, respectively, showed
a clear chemotactic response (Fig. 2A and B). In contrast,
both COOH-terminal peptides markedly inhibited endo-
thelial cell migration in the wound-healing assay contain-
ing a mixture of growth factors (Fig. 2C). CXCL4L1/
PF-4var47-70 inhibited HMVEC migration significantly at
2.5 nmol/L, whereas for CXCL4/PF-447-70 a 5-fold higher
dose was required (Fig. 2D), indicating a stronger angio-
static activity of CXCL4L1/PF-4var47-70 compared withwww.aacrjournals.orgCXCL4/PF-447-70. For comparison, inhibition of endothe-
lial cell migration was obtained at 20 nmol/L CXCL4/PF-
4 or 1 nmol/L CXCL4L1/PF-4var, confirming previously
published data (18, 19). This allowed us to conclude that
CXCL4L1/PF-4var47-70 is equally angiostatic as the intact
chemokine. In the Matrigel assay in vitro also containing a
cocktail of growth factors, a significant inhibition of tube
formation was observed from 60 nmol/L of CXCL4L1/
PF-4var47-70 onwards, whereas CXCL4/PF-447-70 was only
able to reduce the total length of the branches of the net-
works from 300 nmol/L onwards (Fig. 4A). So, in anal-
ogy to the results obtained in the wound-healing assay,
CXCL4L1/PF-4var47-70 is 5-fold more potent than
CXCL4/PF-447-70 as inhibitor of endothelial cell differen-
tiation in the Matrigel assay. We conclude that the twoMol Cancer Res; 8(3) March 2010 329
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330peptides behave in a different manner in different in vitro
test systems for endothelial cell migration. In a growth
factor–specific setting, both peptides inhibited FGF-2–
stimulated endothelial cell motility and proliferation
equally well (Fig. 3A and B). In more complex angiogenesis
systems in which glycosaminoglycans (GAG), extracellular
matrix proteins, a mixture of growth factors, etc. are in-
volved, like in the in vitro Matrigel and wound-healing as-
say, CXCL4L1/PF-4var47-70 is more potent than CXCL4/
PF-447-70 in inhibiting angiogenesis. Further evidence for
this difference in potency was found in the CAM assay
in vivo in which 25 or 5 μg of CXCL4L1/PF-4var47-70,
but not CXCL4/PF-447-70, inhibited the spontaneous for-
mation of blood vessels (46.0% or 30.7% reduction in the
number of blood vessels compared with the control; Fig. 4C
and E). In addition, the angiogenic effect in the presence of
exogenously added FGF-2 was also inhibited more effective-
ly by 5 μg of CXCL4L1/PF-4var47-70 (75.7 ± 9.9% inhibi-
tion) compared with CXCL4/PF-447-70 (47.0 ± 11.5%) in
an alternative gelatin sponge CAM assay (Fig. 4D), indica-
tive for a significant effect of CXCL4L1/PF-4var47-70 on
endogenous mediators.
Finally, the angiostatic activities of CXCL4/PF-447-70
and CXCL4L1/PF-4var47-70 were studied in the B16 mel-
anoma model in athymic nude mice. Struyf et al. (19) al-
ready showed that intratumoral injection of intact
CXCL4L1/PF-4var causes a more pronounced effect than
CXCL4/PF-4 in reducing tumor size in different animal
models, such as B16 melanoma, A549 adenocarcinoma,
and Lewis lung carcinoma. We observed significantly re-
duced tumor growth in the CXCL4L1/PF-4var47-70–trea-
ted, but not in the CXCL4/PF-447-70–treated, group
(seven injections of 1 μg) from day 9 onwards. Moreover,
on day 17, a significantly smaller tumor volume and
weight was found in the CXCL4L1/PF-4var47-70 –treated
mice compared with the control and CXCL4/PF-447-70–
treated mice (Fig. 5). Because we used nude mice, an anti-
tumoral role by infiltrating lymphocytes is excluded.
CD31 staining revealed a significantly lower number of
small and medium-size intratumoral blood vessels in the
CXCL4L1/PF-4var47-70–treated mice compared with the
control and CXCL4/PF-447-70–treated mice (Fig. 6A and
B). However, no differences in vessel stabilization by peri-
cytes could be observed in control versus PF-4 peptide–
treated mice (Fig. 6C and D). Although antiangiogenesis
treatment often increases vessel stabilization, recruitment
of pericytes along endothelial cells is promoted by several
molecules, including platelet-derived growth factor B,
sphingosine 1-phosphate, angiopoietin 1, and transform-
ing growth factor β1 (28), and we do not expect that
CXCL4L1/PF-4var47-70 and CXCL4/PF-447-70 inhibit all
these factors. Furthermore, the pericyte coverage index de-
pends on the type of tumor. Treatment of B16 melanoma
with a platelet-derived growth factor receptor inhibitor
STI571 resulted in decreased tumor growth and vessel
density without affecting the pericyte coverage (29). Thus,
we confirm the findings of Hasumi et al. that monotherapy
of B16 melanoma does not improve vessel stabilization.Mol Cancer Res; 8(3) March 2010In addition, analysis of the B16 melanoma tumor sec-
tions revealed a significantly higher percentage of cells un-
dergoing apoptosis in the CXCL4L1/PF-4var47-70–treated
mice (7.8%), but not in the CXCL4/PF-447-70 group,
compared with the control group (1.0%; Fig. 7A and B).
The fact that we did not observe any significant antitumor-
al effect for CXCL4/PF-447-70 in our tumor model could
be due to the relatively low dose of CXCL4/PF-447-70 ap-
plied (seven injections of 1 μg or 0.02 mg/kg per injection)
compared with previous studies (21, 30, 31). Indeed, otherFIGURE 5. Effect of CXCL4/PF-447-70 and CXCL4L1/PF-4var47-70 on
B16 melanoma growth in vivo. Mice (nu/nu, three independent
experiments) were injected s.c. with 2 × 106 B16 melanoma cells and
received intratumorally vehicle (n = 19 mice), 1 μg CXCL4/PF-447-70
(n = 18 mice), or 1 μg CXCL4L1/PF-4var47-70 (n = 18 mice) per injection
thrice a week from day 1. A, evolution of the average tumor volume
(mean ± SEM) per group [formula: (4πab2)/3 (a and b, largest and smallest
radius, respectively)]. On day 17, tumors were resected, and (B) the
tumor volume (mean ± SEM) was determined [(4πabc)/3 (a, b, and
c represent measured radii)] and the (C) resected tumor weight (mean ±
SEM) was measured. Statistical analysis (Mann-Whitney U test)
indicated a significant difference (*, P < 0.05) between the control mice
and mice treated with CXCL4L1/PF-4var47-70.Molecular Cancer Research
Angiostatic and Antitumoral PF-4var47-70 Peptideresearch groups showed antitumoral activity of CXCL4/
PF-447-70 and of modified fragments of CXCL4/PF-447-70
at higher doses (0.25 mg/kg/d and with continuous admin-
istration using minipumps) in a glioma and glioblastoma
model (20, 21, 32).
The molecular mechanism of the angiostatic and antitu-
moral activities of the CXCL4/PF-4 forms remains unclear.
Several hypotheses have already been proposed for
CXCL4/PF-4 activities. First, a newly identified receptor
variant, named CXCR3-B, could act as a functional recep-www.aacrjournals.orgtor for CXCL4/PF-4 in mediating the inhibition of endo-
thelial cell growth (14). Recently, Mueller et al. (33)
reported that CXCL4/PF-4 at high concentration induces
intracellular calcium release through CXCR3 and attracts
activated T lymphocytes. However, there is no evidence
for the existence of CXCR3-B in mice. In our study, we
injected COOH-terminal peptides composed of 24 amino
acids, lacking the NH2-terminal part essential for GPCR
binding, suggesting that not just CXCR3 binding is neces-
sary for inhibition of angiogenesis. It has also been shownFIGURE 6. Tissue analysis of CXCL4/PF-447-70–treated and CXCL4L1/PF-4var47-70–treated B16 melanoma for angiogenesis and vessel stabilization.
Tissue sections from B16 tumors treated with control solution, 1 μg CXCL4/PF-447-70, or 1 μg CXCL4L1/PF-4var47-70 per injection were evaluated for
angiogenesis and vessel stabilization. A, number (mean ± SEM) of small (area <145.8 μm2), medium-size (area between 145.8 and 2,916 μm2), and
large (area >2,916 μm2) CD31+ blood vessels per mm2 in the peptide-treated mice compared with the control group. *, P < 0.05; ***, P < 0.001,
Mann-Whitney U test. B, representative photographs. Scale bar, 100 μm. C, vessel stabilization was analyzed by staining of pericytes by anti–α-smooth
muscle actin. Results are expressed as mean (± SEM) percentage pericyte-stabilized CD31/α-smooth muscle actin double-positive blood vessels
compared with the total number of CD31-positive blood vessels. For this calculation, vessels were classified in small, medium, and large size.
D, representative photographs of tumor sections stained with anti-CD31 (blue) and anti–α-smooth muscle actin (pink).Mol Cancer Res; 8(3) March 2010 331
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332that CXCL4/PF-4 binds to CXCL8/IL-8 and that they can
form heterodimers (34, 35) with implications on the bio-
logical activities of CXCL4/PF-4, such as enhancement of
the antiproliferative effect (35). Such heterodimers could
also be involved in mediating the angiostatic activities ofMol Cancer Res; 8(3) March 2010CXCL4L1/PF-4var and its COOH-terminal fragment.
Second, the association of chemokines and GAGs facili-
tates the retention of chemokines on cell surfaces and en-
ables the formation of immobilized, or haptotactic,
gradients. This is required for leukocyte recruitment byFIGURE 7. Tissue analysis of CXCL4/PF-447-70–treated and CXCL4L1/PF-4var47-70–treated B16 melanoma for apoptosis. Tissue sections from B16 tumors
treated with control solution, 1 μg CXCL4/PF-447-70, or 1 μg CXCL4L1/PF-4var47-70 per injection were evaluated for apoptosis with the TUNEL assay.
A, data are expressed as a percentage of the apoptotic surface area compared with the total surface area. ***, P < 0.001, Mann-Whitney U test. B,
representative photographs. Cell nuclei were stained with DAPI (blue) and apoptotic cells were visualized in green. Scale bars, 1,000 μm.Molecular Cancer Research
Angiostatic and Antitumoral PF-4var47-70 Peptidemaintaining a high local chemokine concentration (36).
Moreover, chemokine-GAG interaction may facilitate the
receptor binding process. In addition, GAGs are involved
in many processes, such as the control of tumor cell repli-
cation, invasion, and vascularization (37). Further, on neu-
trophils, a chondroitin sulfate proteoglycan receptor has
been identified for CXCL4/PF-4 (38), and on endothelial
cells, a specific heparan sulfate binding site shared between
CXCL4/PF-4 and CXCL10/IP-10 has been evidenced
(39). Third, it has also been shown that CXCL4/PF-4 in-
terferes with the angiogenic effect of FGF-2 and VEGF by
disrupting the interaction of these growth factors with
GAGs. CXCL4/PF-4 can also directly bind to FGF-2, pre-
venting its dimerization, resulting in the inhibition of
binding of this growth factor to its proper receptor and
in the reduction of internalization of FGF-2 (40-42). In
addition, CXCL4/PF-4 inhibits epidermal growth factor–
stimulated proliferation of endothelial cells and interferes
with the cell cycle by impaired downregulation of
p21CIP1/WAF1 (43). Further, it has been shown that differ-
ent CXCL4/PF-4 peptides compete with FGF-2 or VEGF
by inhibiting their binding to FGF or VEGF receptors, re-
spectively, or reduce heparin-induced FGF-2 dimerization,
resulting in the angiostatic activity (21, 31, 44, 45). How-
ever, other mechanisms seem to be involved as well because
an analogue of CXCL4/PF-4 that lacks affinity for heparin
still retains its angiostatic activity (46), and CXCL4/PF-4
also inhibits the function of VEGF-121, an isoform with
deficient heparin-binding ability (47). Recently, an interac-
tion of CXCL4/PF-4 with integrins has been described
that might be implicated in angiogenesis (48). It should
be noted that the mechanism of action of CXCL4/PF-4,
the first identified member of the chemokine family, seems
to be the most complex and consequently the least well
understood.
In summary, this is the first report in which CXCL4L1/
PF-4var47-70 and CXCL4/PF-447-70, differing in only three
amino acids, were compared biologically. Based on differ-
ent in vitro and in vivo assays, we conclude that
CXCL4L1/PF-4var47-70 is a more potent inhibitor of an-
giogenesis and has a more pronounced antitumoral capac-
ity than CXCL4/PF-447-70 without affecting leukocyte
recruitment. In-depth studies are necessary to further clar-
ify the molecular mechanisms through which CXCL4L1/www.aacrjournals.orgPF-4var47-70 exerts its angiostatic and antitumoral activity,
particularly by investigating GPCR and GAG binding, as
well as growth factor interactions. Because of the small size
of the peptide and its ability to inhibit many aspects of the
angiogenic cascade (at relatively low doses), CXCL4L1/PF-
4var47-70 is a promising candidate as an antiangiogenic
drug for cancer treatment and possibly also for other angio-
genesis-dependent diseases. Indeed, identifying small active
fragments of endogenous inhibitors may be useful to re-
duce immunogenicity and increase bioavailability. Applica-
tion of engineered tumor cells or oncotropic viruses (e.g.,
parvovirus) to locally release chemokines, such as mono-
cyte chemotactic protein-3 in melanoma, confirms their
potential clinical value in anticancer therapy (49). In addi-
tion, administration of angiogenesis inhibitors, in combi-
nation with chemotherapy and radiation, remains an
interesting approach for future cancer treatment. Several
antiangiogenic compounds are currently in clinical devel-
opment, as anticancer agents and some drugs, such as
anti-VEGF antibodies, are already used for the treatment
of cancer (50).
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